Compare OVID & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | CYRX |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 419.3M |
| IPO Year | 2017 | 2008 |
| Metric | OVID | CYRX |
|---|---|---|
| Price | $2.74 | $14.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $4.60 | ★ $13.31 |
| AVG Volume (30 Days) | ★ 3.4M | 792.4K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.90 | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | $7,252,000.00 | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | $19.34 | $8.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.36 | $6.69 |
| 52 Week High | $3.11 | $16.73 |
| Indicator | OVID | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 50.93 |
| Support Level | $2.23 | $14.29 |
| Resistance Level | $3.05 | $16.73 |
| Average True Range (ATR) | 0.19 | 0.68 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 86.05 | 29.61 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.